General Report

Autoimmune polyendocrinopathy syndrome with renal damage in children: a clinicopathological analysis of 3 cases

  • Sanlong ZHAO ,
  • Hongmei WU ,
  • Fei ZHAO ,
  • Quancheng FENG ,
  • Chunhua ZHU ,
  • Songming HUANG
Expand
  • Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu, China

Received date: 2022-11-29

  Online published: 2023-12-04

Abstract

Objective To summarize the clinical data of 3 children with autoimmune polyendocrinopathy syndrome (APS) with renal impairment, so as to improve the understanding of the disease. Methods The clinical and renal biopsy pathological data of 3 children with APS complicated with renal damage hospitalized in the Kidney Department of Children's Hospital Affiliated to Nanjing Medical University from February 2018 to February 2023 were retrospectively analyzed. Results Among the 3 patients, 2 were girls and 1 was a boy. The onset age ranged from 1 year and 4 months to 9 years and 11 months. All children with endocrine gland damage presented with autoimmune thyroid disease with type 1 diabetes and were diagnosed with APS type 3. The clinical manifestation of 1 patient was acute renal failure, renal tubular acidosis typeⅠ, and pathological manifestation was tubulointerstitial nephritis. One patient showed hemolytic uremic syndrome, and the renal pathology manifested as thrombotic microangiopathy. One patient had mild tubular proteinuria clinically, and the pathology showed focal tubulointerstitial nephritis. No definite pathogenic gene variation was found in 3 patients. Two patients received oral rapamycin and 1 received a 1-dose infusion of rituximab. After a follow-up from 1 year to 2 years and 7 months, all patients showed normal urinalysis and normal renal function. Conclusions APS type 3 can be associated with renal damage, and its clinical manifestations and renal biopsy pathology are diversified.

Cite this article

Sanlong ZHAO , Hongmei WU , Fei ZHAO , Quancheng FENG , Chunhua ZHU , Songming HUANG . Autoimmune polyendocrinopathy syndrome with renal damage in children: a clinicopathological analysis of 3 cases[J]. Journal of Clinical Pediatrics, 2023 , 41(12) : 937 -941 . DOI: 10.12372/jcp.2023.22e1585

References

[1] Frommer L, Kahaly GJ. Autoimmune polyendocrinopathy[J]. J Clin Endocrinol Metab, 2019, 104(10): 4769-4782.
[2] Sharifinejad N, Zaki-Dizaji M, Tebyanian S, et al. Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review[J]. Expert Rev Clin Immunol, 2021, 17(8): 807-817.
[3] Landegren N, Pourmousa Lindberg M, Skov J, et al. Autoantibodies targeting a collecting duct-specific water channel in tubulointerstitial nephritis[J]. J Am Soc Nephrol, 2016, 27(10): 3220-3228.
[4] Tian S, Xu B, Liu Z, et al. Autoimmune polyglandular syndrome type III associated with antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis: a case report and literature review[J]. Medicine (Baltimore), 2020, 99(7): e19179.
[5] Dikovec C, Wolters K, Vossen LM, et al. MPO-ANCA-associated vasculitis in the context of autoimmune polyglandular syndrome type 3: case report and literature review[J]. Rheumatol Adv Pract, 2022, 6(3): rkac085.
[6] Büyük?elik M, Keskin M, Keskin ?, et al. Autoimmune polyglandular syndrome type 3c with ectodermal dysplasia, immune deficiency and hemolytic-uremic syndrome[J]. J Clin Res Pediatr Endocrinol, 2014, 6(1): 47-50.
[7] Park JH, Lee KH, Jeon B, et al. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: a systematic review[J]. Autoimmun Rev, 2020, 19(6): 102526.
[8] Barzaghi F, Amaya Hernandez LC, Neven B, et al. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study[J]. J Allergy Clin Immunol, 2018, 141(3): 1036-1049.e5.
[9] Pham-Dobor G, Hanák L, Hegyi P, et al. Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III[J]. J Endocrinol Invest, 2020, 43(9): 1-9.
[10] Colao A, Jaffrain-Rea ML, Beckers A. Polyendocrine disorders and endocrine neoplastic syndromes[M]. Switzerland: Springer Nature Switzerland AG, 2021: 5-46.
[11] Improda N, Capalbo D, Cirillo E, et al. Cutaneous vasculitis in patients with autoimmune polyendocrine syndrome type 1: report of a case and brief review of the literature[J]. BMC Pediatr, 2014, 14: 272.
[12] Kurozumi A, Okada Y, Arao T, et al. Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report[J]. Endocr J, 2015, 62(1): 69-75.
Outlines

/